Photo via New York Post

GLP-1 users face 6 rebound risks after stopping the weight-loss drugs

Read the original at New York Post ↗
Cite

Fox News. (2026, November 12). GLP-1 users face 6 rebound risks after stopping the weight-loss drugs. New York Post. https://nypost.com/2026/11/12/health/doctor-reveals-6-rebound-risks-glp-1-users-face-after-stopping/

Dated from the outlet's own feed. Check the original for its byline.

New York Post · collected 2026-11-12 · by Fox News

Quick Summary

Fox News reports on the risks associated with discontinuing GLP-1 weight-loss drugs like Ozempic and Wegovy. Dr. Frank Dumont, an internal medicine physician, highlights that many patients stop using these medications within a year, citing side effects such as nausea and serious concerns like acute pancreatitis. He lists six potential risks of stopping GLP-1 drugs, including the immediate return of intense hunger and cravings, and significant weight regain, with participants in the STEP 1 trial regaining about two-thirds of their lost weight within a year of stopping the medication.
Written by AI on 2026-11-14, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

A new study published in The Lancet Regional Health — Europe suggests that people with type 2 diabetes who start and then stop GLP-1 drugs may face an increased risk of heart attack, stroke, or death compared to those who continue taking the medication. The study, which followed more than 80,000 Italians between 2004 and 2024, found that individuals who discontinued GLP-1 treatments had a risk double that of those who remained on the medication. For those who stopped treatment, four in every 100 experienced a non-fatal heart attack, stroke, or death annually, compared to about two in 100 among those who stayed on the medication. Lead author Antonio Ceriello, head of diabetes research at IRCCS MultiMedica in Italy, noted the association was "not a complete surprise." However, some experts caution that the study cannot prove causation and lacks data on why people stopped using the drugs.

Written for “GLP-1 Rebound Risks Warning” on 2026-11-18, grounded in this article and the 3 other(s) covering the same event.

How they differ

4 outlets covered “GLP-1 Rebound Risks Warning”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

New York PostThis outlet12 Nov

Fox News reports on the risks associated with discontinuing GLP-1 weight-loss drugs like Ozempic and Wegovy. Dr. Frank Dumont, an internal medicine physician, highlights that many patients stop using these medications within a year, citing side effects such as nausea and serious concerns like acute pancreatitis. He lists six potential risks of stopping GLP-1 drugs, including the immediate return of intense hunger…

GLP-1 users face 6 rebound risks after stopping the weight-loss drugs (this article)
ABC News (AU)9 Nov

A new international study published in The Lancet Regional Health—Europe indicates that people with type 2 diabetes who start and then stop using GLP-1 receptor agonists, like Ozempic, may face an increased risk of heart attack, stroke, or death compared to those who continue taking the medication. The research followed over 80,000 Italian participants between 2004 and 2024 and found that approximately four in every…

Study links heart issues to starting and stopping Ozempic-like drugs →
Global News11 Nov

A new study published in the Lancet Regional Health Europe finds that people with type 2 diabetes who stop taking GLP-1 weight loss medications face a doubled risk of heart attack, stroke, or death compared to those who continue their medication. The research, conducted over two decades and involving more than 80,000 Italians, shows that about four in every hundred patients who discontinued the drugs experienced…

Stopping GLP-1 drugs could increase heart attack risk for some, study says →
Fox News12 Nov

Internal medicine physician Dr. Frank Dumont explains the medical risks and side effects associated with GLP-1 medications like Ozempic and Zepbound during an interview with Fox News Digital. He identifies six potential risks after discontinuing the drugs, including the return of intense "food noise" and weight regain, noting that participants in the STEP 1 trial regained about two-thirds of their lost weight within…

Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns →

Compared with similar articles

This article reads unscored and hedges 20% of its claims. Each row says how that neighbour differs.
Fox News
Hedges 11 of 48 claims Outlet record 67/100
Global News
Hedges 6 of 27 claims Outlet record 63/100

Story

GLP-1 Rebound Risks Warning
Health · 4 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
45
sentences that state something as happening or true
Uncertain
20%
9 of 45 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
New York Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
4
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-14 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

New York Post · 21098 article(s) · 41 correction(s) detected
Running correction rate · 41 correction(s)

Who wrote this

Fox News
514 article(s) here · 1 carrying a prediction
The soldiers identified were Cpl. Jackie Lee Thurman, 18, of Illinois; 1st Lt. Raymond Banker Gilbert, 23, of Ohio; Cpl. Richard Neal Lennox, 18, of Michigan; Cpl. William Reynold Laughlin Jr., 21, of Oregon; Sgt. Joseph Alfred Platzkoester, 28, of Illinois; and Cpl. Andrew R. Tischler, 21, of Celina, Texas.
They also would not say whether anyone else may have been involved.
“These are extremely serious allegations, and our collective response should send a strong message that we will act swiftly and robustly where we suspect this kind of espionage activity taking place,” Taylor said in a statement.
Thomas was joined by Justice Samuel Alito in dissenting from the decision, arguing that allowing the law to stand could have implications reaching far beyond the medical field.
Christian convert could face execution in Egypt as State Department monitors trial
Upon taking office, New York City Mayor Zohran Mamdani signed an executive order limiting city coordination with ICE, and a state law signed by Gov. Kathy Hochul took effect in August barring local authorities from cooperating with federal immigration officials.
Khanna, a frequent critic of President Donald Trump’s war in the Middle East, said the checks would be sent to every American family to reimburse them for the higher gas, food and electricity prices sparked by the conflict and resulting disruptions to oil transport routes.
The developments came days before President Donald Trump is expected to meet Putin and Chinese President Xi Jinping in China, amid renewed US-brokered efforts to end the nearly five-year conflict.
The Ravens will lean on Derrick Henry and a ball-control approach, especially with extra rest and a home crowd behind them.
In a game expected to land in the 30s, 4.5 points is a real cushion.
Wire or desk byline, not an individual reporter.
Also by Fox News
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 514 articles by Fox News →

Topics

Dumont Fox News Fox News Digital Ozempic Wegovy

Subjects

Dumont PERSON · 8× Fox News Digital ORG · 2× AMA ORG · 1× Angelica Stabile PERSON · 1× Fox News ORG · 1× Frank Dumont PERSON · 1× San Francisco GPE · 1× Virta Health ORG · 1× the American Medical Association ORG · 1× the Obesity Medicine Association ORG · 1×

Narrative

In the SURMOUNT-4 trial for tirzepatide, patients who were switched to a placebo after 36 weeks of treatment regained more than half the weight they had lost over the following year, even while receiving diet and exercise counseling. “That’s just so devastating for people who felt like they’d finally found a solution that would work,” Dumont said.
framing: assertive · carried by 1 article(s) · first seen 2026-11-14
Why patients stop Some patients may stop taking GLP-1 medications because of medical concerns or side effects, while others prefer not to remain on long-term medication, Dumont said.
2026-11-14 · New York Post
GLP-1 users face 6 rebound risks after stopping the weight-loss drugs · assertive framing

Claims (45 extracted, 9 hedged)

GLP-1 users face 6 rebound risks after stopping the weight-loss drugs By asserted
users → face → drugs
While GLP-1 medications like Ozempic, Wegovy and Zepbound have reshaped weight management and diabetes control, research shows that many patients stop taking them within a year. asserted
patients → reshape → year
Research has found that cycling off these medications can bring potential rebound risks, ranging from rapid weight regain to the loss of cardiovascular protection. asserted
cycling → find → protection
Dr. Frank Dumont, internal medicine physician and executive medical director at Virta Health in San Francisco, spoke with Fox News Digital about why patients stop taking GLP-1s, the potential risks and how to maintain progress afterward. asserted
patients → speak → progress
Why patients stop Some patients may stop taking GLP-1 medications because of medical concerns or side effects, while others prefer not to remain on long-term medication, Dumont said. uncertain
Dumont → stop → medication
Common side effects include nausea, vomiting, constipation and diarrhea. asserted
effects → include → nausea
“Those types of things can become troublesome enough that people actually have a hard time eating enough food to get good nourishment,” he told Fox News Digital. asserted
he → become → Digital
“Working with your physician to make a decision about whether it’s right for you to stay on the medicine or not is important. asserted
you → work → medicine
Other serious side effects, like acute pancreatitis, would prompt immediate discontinuation of the drug. asserted
effects → prompt → drug
“We know that’s fairly rare, but if the pancreas becomes involved, that is not a good thing,” Dumont said. asserted
Dumont → know → ?
It can even be life-threatening.” asserted
It → threaten → ?
Certain GLP-1 medications carry a warning about thyroid tumors based on animal studies, though the risk in humans remains unknown. asserted
risk → carry → humans
These medications should not be used by people with a personal or family history of medullary thyroid carcinoma or a condition called multiple endocrine neoplasia syndrome type 2 (MEN 2). asserted
medications → use → carcinoma
Dumont outlined six potential risks patients may face after stopping a GLP-1. No. 1: Return of hunger and cravings The most immediate side effect patients notice after stopping a GLP-1 is the return of intense cravings and a sharp spike in appetite, often referred to as “food noise,” according to Dumont. uncertain
patients → outline → Dumont
Many patients assume they can treat GLP-1s like a short-term prescription, taking the drug to hit a target weight or blood sugar goal and then stopping, the doctor noted. asserted
doctor → assume → goal
However, major medical organizations, including the American Medical Association (AMA) and the Obesity Medicine Association, classify obesity as a chronic condition that typically requires ongoing management. asserted
that → include → management
“Unless you have significantly changed what you’re doing in terms of the types of foods you’re eating, it’s likely you’ll go back to the same foods you were eating before, and hunger and cravings will go up,” Dumont said. asserted
Dumont → change → foods
No. 2: Weight regain It is typical for GLP-1 users to experience weight regain after quitting, according to Dumont. uncertain
users → experience → Dumont
In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping semaglutide and lifestyle interventions. asserted
they → regain → semaglutide
In the SURMOUNT-4 trial for tirzepatide, patients who were switched to a placebo after 36 weeks of treatment regained more than half the weight they had lost over the following year, even while receiving diet and exercise counseling. “That’s just so devastating for people who felt like they’d finally found a solution that would work,” Dumont said. asserted
Dumont → switch → solution
No. 3: Change in biomarkers Biomarkers — which are measurable indicators of what’s happening inside the body, such as blood sugar, blood pressure and cholesterol levels — tend to improve while taking a GLP-1, which is beneficial for those with prediabetes or diabetes. asserted
which → happen → prediabetes
When a GLP-1 is stopped, these markers can reverse if not countered with a change in diet, according to Dumont. uncertain
markers → stop → Dumont
Improvements in fatty liver disease may also fade after treatment stops, the doctor said. uncertain
doctor → fade → disease
“We know that these medications can help to decrease some of that steatotic or fatty liver disease that occurs,” he noted. asserted
he → know → disease
“And when you go off the medicine, if you go back to eating the way you did before, those numbers have a tendency to worsen.” asserted
numbers → go → tendency
“When people take the GLP-1 medications, they lose weight, but they tend to lose both fat mass and lean muscle mass,” he told Fox News Digital. asserted
he → take → Digital
In a body-composition study of tirzepatide, about 25% of the weight lost was lean mass, which includes muscle and other nonfat tissue. asserted
which → lose → muscle
The remaining 75% was fat. asserted
% → remain → ?
Dumont expressed concern that patients who regain weight after stopping treatment may not fully replace the muscle they lost. uncertain
they → express → muscle
“So, there’s a bit of a ratcheting-down effect if someone is on and off these medications, where they lose fat and muscle, stop the medicine, regain fat, go back on the medicine, and lose fat and muscle,” he added. asserted
he → ’ → fat
The doctor emphasized that preserving muscle is important for metabolism, injury prevention and everyday activities. asserted
preserving → emphasize → metabolism
In addition to the physical consequences, Dumont noted that stopping a weight-loss drug can take a heavy toll on mental health. asserted
stopping → note → health
Many patients have spent years cycling through diets and programs without lasting success, often viewing GLP-1s as a final solution, according to the doctor. Keep up with today’s most important news Stay up on the very latest with Evening Update. When the medication isn’t right for them — adding to a history of past weight-loss setbacks — experiencing a “regression on all fronts” can be “really devastating from a mental health standpoint,” Dumont said. “It can make you feel disheartened and like you don’t have the control you thought you did,” he added. uncertain
he → spend → control
No. 6: Loss of health protection An observational study published in BMJ Medicine found that adults with type 2 diabetes who stopped GLP-1 treatment had a higher risk of major cardiovascular events than those who continued. asserted
who → publish → those
Longer periods without treatment were associated with greater risk. asserted
periods → associate → risk
Dumont noted that the stakes of stopping a GLP-1 go far beyond weight, pointing to the broader risk of losing metabolic benefits. asserted
stakes → note → benefits
While taking a GLP-1, lower inflammation and improved cholesterol and blood sugar levels help reduce the risk of major events like heart attacks and strokes, the doctor said. asserted
doctor → take → attacks
“But again, if you stop the medicine and you haven’t changed the way that you eat, then all of those numbers can worsen … and that can then increase the risk of those bad things happening — things that can be devastating from a life quality standpoint, but also can shorten your life,” he warned. asserted
he → stop → life
Making your progress last Reaching metabolic goals and making lasting lifestyle changes may help patients maintain their progress after stopping a GLP-1, according to Dumont. uncertain
patients → make → Dumont
“We actually have peer-reviewed published data demonstrating that you can indeed stop one of these medications when you reach your metabolic goals,” he said. asserted
he → have → goals
…and 5 more, not listed.
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support